Danuta Galetzka
Overview
Explore the profile of Danuta Galetzka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grandt C, Brackmann L, Poplawski A, Schwarz H, Marini F, Hankeln T, et al.
Front Oncol
. 2023 May;
13:1158176.
PMID: 37182169
Introduction: Long non-coding ribonucleic acids (lncRNAs) are involved in the cellular damage response following exposure to ionizing radiation as applied in radiotherapy. However, the role of lncRNAs in radiation response...
2.
Brackmann L, Foraita R, Schwarz H, Poplawski A, Hankeln T, Galetzka D, et al.
Front Oncol
. 2023 May;
13:1150629.
PMID: 37124517
Background: Childhood cancer survivors (CCS) are at particularly high risk for therapy-related late sequelae, with secondary primary neoplasms (SPN) being the most detrimental. Since there is no standardized questionnaire for...
3.
Grandt C, Brackmann L, Foraita R, Schwarz H, Hummel-Bartenschlager W, Hankeln T, et al.
Mol Med
. 2023 Mar;
29(1):41.
PMID: 36997855
Background: Differential expression analysis is usually adjusted for variation. However, most studies that examined the expression variability (EV) have used computations affected by low expression levels and did not examine...
4.
Zahnreich S, Yusifli K, Poplawski A, Eckhard L, Mirsch J, Hankeln T, et al.
DNA Repair (Amst)
. 2022 Dec;
122:103435.
PMID: 36549044
New development and optimization of oncologic strategies are steadily increasing the number of long-term cancer survivors being at risk of developing second primary neoplasms (SPNs) as a late consequence of...
5.
Brackmann L, Foraita R, Schwarz H, Galetzka D, Zahnreich S, Hankeln T, et al.
Front Oncol
. 2022 Nov;
12:1037276.
PMID: 36324589
Background: Improved treatments for childhood cancer result in a growing number of long-term childhood cancer survivors (CCS). The diagnosis and the prevalence of comorbidities may, however, influence their lifestyle later...
6.
Grandt C, Brackmann L, Poplawski A, Schwarz H, Hummel-Bartenschlager W, Hankeln T, et al.
Mol Med
. 2022 Sep;
28(1):105.
PMID: 36068491
Background: The etiology and most risk factors for a sporadic first primary neoplasm in childhood or subsequent second primary neoplasms are still unknown. One established causal factor for therapy-associated second...
7.
Galetzka D, Bock J, Wagner L, Dittrich M, Sinizyn O, Ludwig M, et al.
EXCLI J
. 2022 Feb;
21:117-143.
PMID: 35221838
Most childhood cancers occur sporadically and cannot be explained by an inherited mutation or an unhealthy lifestyle. However, risk factors might trigger the oncogenic transformation of cells. Among other regulatory...
8.
Marron M, Brackmann L, Schwarz H, Hummel-Bartenschlager W, Zahnreich S, Galetzka D, et al.
JMIR Res Protoc
. 2021 Nov;
10(11):e32395.
PMID: 34762066
Background: Therapy for a first primary neoplasm (FPN) in childhood with high doses of ionizing radiation is an established risk factor for second primary neoplasms (SPN). An association between exposure...
9.
Legscha K, Antunes Ferreira E, Chamoun A, Lang A, Awwad M, Ton G, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34112738
Background: Tumor microenvironment-associated T cell senescence is a key limiting factor for durable effective cancer immunotherapy. A few studies have demonstrated the critical role of the tumor suppressor TP53-derived p53...
10.
Galetzka D, Muller T, Dittrich M, Endres M, Kartal N, Sinizyn O, et al.
J Mol Med (Berl)
. 2020 Sep;
98(11):1657.
PMID: 32978668
The correct Author names are presented in this paper.